Production (Stage)
Bright Minds Biosciences Inc.
DRUG
CNSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 13.03% | -14.46% | -35.42% | -29.56% | -34.25% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 0.10% | -61.83% | -63.97% | -61.01% | -49.64% |
| Operating Income | -0.10% | 61.83% | 63.97% | 61.01% | 49.64% |
| Income Before Tax | 37.96% | 84.28% | 62.35% | 59.86% | 48.76% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 37.96% | 84.28% | 62.35% | 59.86% | 48.76% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 37.96% | 84.28% | 62.35% | 59.86% | 48.76% |
| EBIT | -0.10% | 61.83% | 63.97% | 61.01% | 49.64% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 62.87% | 86.49% | 65.63% | 65.55% | 60.90% |
| Normalized Basic EPS | 62.90% | 86.50% | 65.63% | 65.54% | 60.89% |
| EPS Diluted | 62.84% | 86.33% | 65.43% | 65.48% | 60.72% |
| Normalized Diluted EPS | 62.71% | 86.36% | 65.53% | 65.47% | 60.89% |
| Average Basic Shares Outstanding | 39.69% | 28.95% | 15.59% | 18.86% | 26.62% |
| Average Diluted Shares Outstanding | 43.86% | 33.31% | 16.83% | 20.19% | 26.62% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |